Mezigdomide Triplet Improves PFS in R/R Multiple Myeloma Edited by Gargi Mukherjee Blood. 2026; doi:10.1182/blood.2025032270

https://www.medscape.com/viewarticle/mezigdomide-triplet-improves-pfs-r-r-multiple-myeloma-2026a1000lzr?src= Mezigdomide in combination with carfilzomib and dexamethasone more than doubled the median progression-free survival (PFS) compared with carfilzomib-dexamethasone in patients with relapsed or refractory (R/R) multiple myeloma, though rates of grade 3 or 4 adverse events, including infections, were higher with the mezigdomide triplet regimen.